Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)
Company Announcements

Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)

Arcus Biosciences Inc (RCUS) has released an update to notify the public and investors about the unregistered sales of equity securities.

The Gilead Financing details referenced earlier pertain to shares sold to Gilead under Section 4(a)(2) of the Securities Act of 1933. The transaction was made with an accredited investor entity.

For further insights into RCUS stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskArcus Biosciences Reports Q3 2024 Results
TheFlyArcus Biosciences reports Q3 EPS ($1.00), consensus ($1.06)
TheFlyArcus Biosciences announces results from Part 1 of ARC-10 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App